Hehuang Pharmaceutical (00013) issued an announcement. The group announced today that it will run from April 5, 2024 to...
Zhitong Finance App News, Hehuang Pharmaceutical (00013) announced today that the group will announce the latest and updated data from several studies on compounds independently developed by Huhuang Pharmaceutical at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) to be held in San Diego, California, USA from April 5 to 10, 2024.
Preliminary preclinical data on the novel, potent, and differentiated menin-MLL inhibitor HMPL-506 will be presented at the conference to treat specific types of acute leukemia. HMPL-506 showed stronger inhibitory activity in leukemia cell line models of MLL rearrangement and NPM1 mutations compared to five other menin inhibitors currently under clinical development. Furthermore, in vitro and in vivo tests, HMPL-506 was used in combination with azacytidine (azacytidine), venetoclax (venetoclax), or gilteritinib (gilteritinib) to have a synergistic anti-tumor effect in MLL-rearranged leukemia. The candidate drug under study showed good pharmacokinetic characteristics, high selectivity, and low risk of cardiotoxicity. Phase I of the HMPL-506 study is scheduled to commence in the second half of 2024.
Preliminary preclinical data on the novel CD38 targeting antibody conjugate drug (ADC) HMPL-A067 (HMA800067) will also be published. It is a drug that couples daratumumab (daratumumab) with cytotoxic load monomethyl auristatin E (MMAE) through a novel ligand. It showed significantly superior anti-tumor activity to daretuumab in several B-cell malignancy models, including daretuizumab resistant tumor models.
Other published data include preclinical data for the ERK 1/2 inhibitor HMPL-295; early clinical data with the Syk inhibitor sovleplenib (sovleplenib) in lymphoma patients; additional clinical data from a global study of the VEGFR inhibitor fruquintinib (fruquintinib) and the MET inhibitor savolitinib (savolitinib); and fruquintinib, a VEGFR/CSF-1R/FGFR inhibitor ( surufatinib) research.